U.S. Hospitality Stock News

NasdaqGM:JFIN
NasdaqGM:JFINConsumer Finance

Jiayin Group (NasdaqGM:JFIN) Margins Jump to 26.2%, Reinforcing Bullish Profitability Narratives

Jiayin Group (NasdaqGM:JFIN) posted total revenue of ¥1.47 billion and basic EPS of ¥7.34 for the third quarter of 2025, accompanied by a net income of ¥376.49 million. The company has seen revenue move from ¥1.44 billion in Q3 2024 to ¥1.47 billion in Q3 2025, while EPS climbed from ¥5.07 to ¥7.34 over the same period. These results point to expanding margins and a favorable profit backdrop heading into the next reporting cycle. See our full analysis for Jiayin Group. Next up, we’re...
NasdaqGM:RNAM
NasdaqGM:RNAMBiotechs

Will FDA Accelerated Pathway for Delpacibart Zotadirsen Reshape Avidity Biosciences' (RNA) Rare Disease Trajectory?

In November 2025, Avidity Biosciences announced the launch of its Managed Access Program for the investigational therapy delpacibart zotadirsen for eligible Duchenne muscular dystrophy (DMD44) patients in the United States, aligning with the FDA on a 2026 accelerated approval submission pathway. This move reflects significant clinical and regulatory progress, as the therapy has earned multiple expedited designations from both U.S. and European regulators. We'll explore how securing FDA...
NYSE:EL
NYSE:ELPersonal Products

3 Stocks That May Be Trading Below Their Estimated Value

As the U.S. stock market experiences a notable upswing with major indexes like the Nasdaq, S&P 500, and Dow Jones Industrial Average showing significant gains entering the Thanksgiving holiday, investors are increasingly attentive to opportunities that may be trading below their estimated value. In such a buoyant environment, identifying stocks that are potentially undervalued can provide investors with strategic entry points to capitalize on broader market optimism while maintaining a focus...
NasdaqGS:CGEM
NasdaqGS:CGEMBiotechs

Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics recently announced the initiation of a rolling New Drug Application submission to the U.S. FDA for accelerated approval of zipalertinib, targeting EGFR exon 20 insertion-mutated non-small cell lung cancer after chemotherapy. This milestone builds on zipalertinib’s Breakthrough Therapy Designation and leverages data from the REZILIENT1 Phase 1/2 trial involving previously treated patients. We'll explore how progress toward FDA...
NYSE:HBI
NYSE:HBILuxury

Hanesbrands (HBI): Assessing Valuation as Investors Weigh Mixed Fundamentals and Recent Modest Gains

Hanesbrands (HBI) recently posted modest gains, with shares ticking up about 1% over the past week. Investors are weighing the company's mixed fundamentals as the consumer durables sector undergoes shifts and retail demand trends continue to evolve. See our latest analysis for Hanesbrands. Hanesbrands has seen its share price rebound slightly over the past quarter, but momentum remains mixed after a tough year, with a 1-year total shareholder return of -25.11%. While short bursts of optimism...
NYSE:UAA
NYSE:UAALuxury

3 Promising Penny Stocks With Over $900M Market Cap

As U.S. stock indexes have recently surged, with the Dow climbing over 650 points in a single day, investors are increasingly seeking opportunities beyond the usual market leaders. Penny stocks, while often associated with speculative trading, can still offer significant potential when supported by robust financials. This article will explore several penny stocks that combine strong balance sheets with promising growth prospects, demonstrating that even in today's evolving market landscape,...